Centene Corporation

$19.00

SKU: CNC Category:

Description

Centene Corporation managed to exceed analyst expectations in terms of revenue as well as earnings. The second quarter results proved Centene’s capacity to produce reliable results in a dynamic healthcare environment. For the quarter, they increased their expectation for 2023 premium and service revenue by an additional $1.8 billion. In terms of progression, the outpatient trend increased. The commercial HBR met the company’s expectations, considering the quarter’s 200,000 new members and the marketplace’s ongoing robust growth. Besides, Centene has a valuable potential with Medicare Advantage to help seniors with medical complexity and limited income. They also continue to have success with their Ambetter Health franchise. The execution of their new PBM contract is proceeding as planned. In the quarter, Centene completed the sale of Apixio to New Mountain Capital. Their team believes that collaborating with New Mountain will enable Apixio to evolve quickly through continuous investment while they remain an influential customer and minority stakeholder. This is an excellent illustration of their deliberate attempts to optimize long-term value as they reposition their company. Overall, Centene continued to produce strong financial results for the quarter while carrying out a long list of transformative projects to advance its business. We give Centene Corporation a ‘Hold’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!